RET and medullary thyroid gland carcinoma: In 9 of the 18 mutation-carrier relatives diagnosed with MTC/CCH after RET screening, diagnoses for MTC had already been made possible by their clinical evaluations, as they had sCt levels above 100 pg/mL along with a suspicious thyroid nodule on US and/or FNAB thyroid nodule or cervical LN cytology results that were suspicious for malignancy (Table 1).